<DOC>
	<DOCNO>NCT02229851</DOCNO>
	<brief_summary>This study conduct globally . The purpose demonstrate efficacy weekly dose NNC0195-0092 compare placebo once-daily dose somatropin ( human growth hormone , hGH ) 35 week treatment adult growth hormone deficiency .</brief_summary>
	<brief_title>Trial Compare Efficacy Safety NNC0195-0092 With Placebo Norditropin® FlexPro® Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female least 23 year age 79 year age time sign informed consent Human growth hormone ( hGH ) treatment naïve exposure hGH growth hormone ( GH ) secretagogues least 180 day prior randomisation register investigational hGH GH secretagogue product ( used connection stimulation test diagnosis growth hormone deficiency ( GHD ) , subject include ) If applicable , hormone replacement therapy hormone deficiency , adequate stable least 90 day prior randomisation judge investigator FOR ALL COUNTRIES EXCEPT JAPAN : Confirmed diagnosis adult growth hormone deficiency ( Subjects must satisfy one follow criterion documentation test result must available randomisation ( either subject ' file new test ) : a. Insulin tolerance test ( ITT ) glucagon test : peak GH response le 3 ng/mL ( 3 mcg/L ) b . Growth hormone release hormone ( GHRH ) + arginine test accord body mass index ( BMI ) : ) BMI le 25 kg/m^2 , peak GH le 11 ng/mL ( 11 mcg/L ) , ii ) BMI 2530 kg/m^2 , peak GH le 8 ng/mL ( 8 mcg/L ) , iii ) BMI great 30 kg/m^2 , peak GH le 4 ng/mL ( 4 mcg/L ) c. Three pituitary hormone deficiencies insulin like growth factor I standard deviation score ( IGFI SDS ) less 2.0 FOR JAPAN ONLY : Confirmed diagnosis adult growth hormone deficiency ( subject adult onset adult growth hormone deficiency ( AGHD ) need satisfy least one follow criterion , subject history childhood GHD need satisfy least 2 follow criterion ) : a. ITT test : peak GH le equal 1.8 ng/mL ( assay use recombinant GH standard ) b. glucagon test : peak GH le equal 1.8 ng/mL ( assay use recombinant GH standard ) c. growth hormone release peptide 2 ( GHRP2 ) tolerance test : peak GH le equal 9 ng/mL ( assay use recombinant GH standard ) Active malignant disease history malignancy . Exceptions exclusion criterion : Resection situ carcinoma cervix uterus . Complete eradication squamous cell basal cell carcinoma skin Subjects GHD attribute treatment intracranial malignant tumour leukaemia , provide recurrencefree survival period least 5 year document subject 's file</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>